News
NVAX
4.930
+4.67%
0.220
Recent uptick might appease Novavax, Inc. (NASDAQ:NVAX) institutional owners after losing 35% over the past year
A total of 15 investors have a majority stake in Novavax, Inc. (NASDAQ:NVAX) with 50% of the company. The company is owned by institutions with a 47% stake in the company, and is expected to grow in the future. The majority of the shares are owned by a group of 15 institutional investors. NovavAX has a history of growth but the company is not well known to the general public. It's worth looking at the company's insider ownership to see if there are any signs of insider buying.
Simply Wall St · 2d ago
Russell 2000 Q1 2024 Earnings Preview: Sharp Downward Revisions Precede Earnings Season
Seeking Alpha · 2d ago
How Is The Market Feeling About Novavax?
Novavax's short percent of float has fallen 8.76% since its last report. The company has 43.91 million shares sold short, which is 36.57% of all regular shares available for trading. Short interest is the number of shares that have been sold short but have not yet been covered.
Benzinga · 2d ago
Novavax (NVAX) Increases Despite Market Slip: Here's What You Need to Know
NASDAQ · 3d ago
What's in the Cards for Amgen (AMGN) This Earnings Season?
NASDAQ · 5d ago
3 Beaten-Down Stocks I Wouldn't Touch With a 10-Foot Pole
NASDAQ · 5d ago
Weekly Report: what happened at NVAX last week (0422-0426)?
Weekly Report · 5d ago
WHO picks JN.1 variant for next set of COVID vaccines
Healthcare WHO picks JN.1 variant for next set of COVID vaccines. World Health Organization recommended drugmakers to update their vaccine formulations to reflect the currently dominant SARS-CoV-2 variant, Jn.1. The currently approved vaccines are designed to target the XBB.5 Omicron subvariant.
Seeking Alpha · 6d ago
NOVAVAX :PREPARED TO DELIVER PROTEIN-BASED NON-MRNA JN.1 COVID-19 VACCINE IN LINE WITH WHO RECOMMENDATION THIS FALL
Reuters · 04/26 18:11
How Should You Play Merck (MRK) Stock Ahead of Q1 Earnings?
NASDAQ · 04/22 18:39
Weekly Report: what happened at NVAX last week (0415-0419)?
Weekly Report · 04/22 09:08
These Biotech Stocks Could Soar 120% and 295%, According to Wall Street
Two biotech companies are expected to soar over the coming 12 months. Iovance Biotherapeutics recently won accelerated approval for its first cancer treatment. Novavax is a vaccine company that could be a growth stock in the future. Both companies offer great long-term prospects. Wall Street is optimistic about two of these companies.
The Motley Fool · 04/21 09:08
What's in Store for Biogen (BIIB) This Earnings Season?
NASDAQ · 04/19 13:39
NOVAVAX TO SUPPLY UPDATED COVID-19 VACCINE TO PRIVATE HEALTHCARE PROVIDERS IN THE UNITED KINGDOM
Reuters · 04/18 12:00
BUZZ-U.S. STOCKS ON THE MOVE-Snap One, Encore Wire, Centene
The Dow Jones Industrial Average was down 0.45% on Monday. Goldman Sachs boosted by robust gains. Snap One, Encore Wire, Centene were among the top stocks on the NYSE. The S&P 500 and Nasdaq Composite both fell on the day. U.S. Retail sales were stronger than expected.
Reuters · 04/15 17:48
BUZZ-U.S. STOCKS ON THE MOVE-Cisco Systems, Inspired Entertainment, Spirit Airlines
Dow Jones Industrial Average was up 0.36% at 38,119.77. Goldman Sachs boosted by robust gains. Top three S&P 500 percentage gainers: M&T Bank, Centene, Snap One. Apple down 0.6% after falling in premarket trading.
Reuters · 04/15 16:13
BUZZ-U.S. STOCKS ON THE MOVE-Encore Wire, Masimo, Goldman Sachs
Wall Street's main stock indexes eyed a higher open on Monday. Dow e-minis up 0.82%, S&P 500 and Nasdaq 100 also up. Goldman Sachs, Encore Wire, Masimo, Lockheed Martin among top stocks on the move. Tensions in the Middle East make investors wary of the U.S.
Reuters · 04/15 13:26
What's Going On With Novavax Stock Today?
Shah Capital Management reported a 6.66% stake in Novavax Inc. The hedge fund has nominated two new directors for the company's board. Shah Capital says it is disappointed with the recent performance of the company. The company's shares are trading higher Monday.
Benzinga · 04/15 13:14
Shah Capital calls for board shake-up at Novavax
Healthcare Shah Capital calls for board shake-up at Novavax. The hedge fund is a top-five shareholder in the company. The fund identifies ongoing operating losses, marketing failures, and questionable regulatory management among issues plaguing the firm. Shah Capital has nominated two independent director candidates for the board.
Seeking Alpha · 04/15 11:48
BUZZ-U.S. STOCKS ON THE MOVE-Longeveron, Novavax, Telsa
U.S. Stock index futures rise on Monday. Dow and S&P 500 e-minis up 0.47% and 0.55% respectively. Longeveron, Novavax, Telsa among top Nasdaq percentage gainers. Wall Street suffered a bruising sell-off in the previous session.
Reuters · 04/15 11:47
More
Webull provides a variety of real-time NVAX stock news. You can receive the latest news about Novavax Inc through multiple platforms. This information may help you make smarter investment decisions.
About NVAX
Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and Nuvaxovid updated COVID-19 vaccine (NVX-CoV2601 or updated vaccine) (collectively, COVID-19 Vaccine). The Company is advancing the development of other vaccine candidates, including its COVID19-Influenza Combination (CIC) vaccine candidate and additional vaccine candidates. Its COVID-19 Vaccine and its other vaccine candidates incorporate the Company’s proprietary Matrix-M adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.